GlassScriptPhysician profile
Payam Soltanzadeh
NPI 1659506491
$9,487.69
in general payments reported to CMS, 2019-2025
17 companies · $783 in 2025
The $783 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $3,900 · 2021: $58.31 · 2022: $2,253 · 2023: $400 · 2024: $1,827 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,247 · Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,246.57 |
| Food and Beverage | $763.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $4,802.61 | 2020-2025 | |
| Argenx US, INC. | $1,725.00 | 2022 | |
| Pfizer INC. | $1,656.75 | 2024 | |
| Alexion Pharmaceuticals, INC. | $321.75 | 2019-2024 | Ultomiris |
| Ptc Therapeutics, INC. | $233.13 | 2022-2024 | Emflaza |
| Ucb, INC. | $204.98 | 2023-2025 | Zilbrysq, Rystiggo |
| Grifols USA, LLC | $147.39 | 2022 | |
| Ns Pharma, INC. | $146.59 | 2021-2025 | Viltepso |
| Alnylam Pharmaceuticals INC. | $125.00 | 2019 | |
| Tanabe Pharma America, INC. | $32.18 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.79 | 2022 | |
| Genentech USA, INC. | $22.26 | 2024 | Evrysdi |
| Itf Therapeutics LLC | $21.32 | 2025 | |
| Biogen, INC. | $21.11 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payam Soltanzadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.